Shares of Praxis Precision Medicines, Inc. PRAX were down 78.1% on Monday after the company announced disappointing data from the phase II/III Aria study that evaluated its pipeline candidate, ...
Praxis Precision Medicines, Inc. (PRAX) stock is soaring in trading today, up 35% at time of writing, with shares reaching a value of $260, their highest value since the beginning of 2022. Current ...
BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies ...
BOSTON - Praxis Precision Medicines Inc. (NASDAQ: PRAX) announced that the Independent (LON:IOG) Data Monitoring Committee (IDMC) has recommended halting Study 1 of the Essential3 program, which is ...
BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results